Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab Continuation Study in RA
NCT00195650Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Jul 2000
- Primary completion
- May 2011
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in rheumatoid arthritis (RA), sponsored by Abbott Laboratories. Primary endpoints: American College of Rheumatology 20% Response at 520 weeks, American College of Rheumatology 50% Response at 520 weeks and 3 more. Started Jul 2000; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00195650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00195650.